Alexion taps ex-Baxalta exec Hantson as CEO

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) named Ludwig Hantson CEO. He was president and CEO of Baxalta Inc., which Shire plc (LSE:SHP; NASDAQ:SHPG) acquired in 2016.

David Brennan had been Alexion's interim CEO since December 2016, when CEO David Hallal and CFO Vikas Sinha left the company amid an investigation of the company's sales practices for Soliris eculizumab. The company later clarified its accounting procedures, and said it would not have to restate previously issued financial results (see BioCentury Extra, Jan. 5)...